Get the Stockscreener App
3.94
3.43%
-0.14
After Hours:
3.97
0.03
+0.76%
Tango Therapeutics Inc stock is traded at $3.94, with a volume of 494.82K.
It is down -3.43% in the last 24 hours and down -34.33% over the past month.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
See More
Previous Close:
$4.08
Open:
$4.08
24h Volume:
494.82K
Relative Volume:
0.27
Market Cap:
$423.23M
Revenue:
$42.51M
Net Income/Loss:
$-116.49M
P/E Ratio:
-3.2562
EPS:
-1.21
Net Cash Flow:
$-120.82M
1W Performance:
+0.51%
1M Performance:
-34.33%
6M Performance:
-41.63%
1Y Performance:
-47.47%
1-Day Range:
$3.94
$4.21
1-Week Range:
$3.63
$4.21
52-Week Range:
$2.70
$13.01
Tango Therapeutics Inc Stock (TNGX) Company Profile
Name
Tango Therapeutics Inc
Sector
Industry
Phone
(857) 320-4900
Address
201 BROOKLINE AVENUE, BOSTON
Compare TNGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
3.94 | 423.23M | 42.51M | -116.49M | -120.82M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-17-24 | Initiated | Jefferies | Buy |
| Apr-04-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-24 | Initiated | Piper Sandler | Overweight |
| Dec-08-23 | Initiated | B. Riley Securities | Buy |
| Oct-20-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-20-21 | Initiated | SVB Leerink | Outperform |
View All
Tango Therapeutics Inc Stock (TNGX) Latest News
Tango Therapeutics, Inc. (NASDAQ:TNGX) Short Interest Update - MarketBeat
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference - StockTitan
Tango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
Tango Therapeutics director Mace Rothenberg acquires $74,000 in stock By Investing.com - Investing.com Canada
Tango Therapeutics director Mace Rothenberg acquires $74,000 in stock - Investing.com
Trv Gp Iv LLC Cuts Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - MarketBeat
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
B. Riley Increases Earnings Estimates for Tango Therapeutics - Defense World
B. Riley Forecasts Higher Earnings for Tango Therapeutics - MarketBeat
B. Riley Cuts Tango Therapeutics (NASDAQ:TNGX) Price Target to $8.00 - Defense World
Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 inhibitor progress - Investing.com
Tango Therapeutics (NASDAQ:TNGX) Earns “Buy” Rating from HC Wainwright - Defense World
The Analyst Landscape: 5 Takes On Tango Therapeutics - Benzinga
B. Riley Has Lowered Expectations for Tango Therapeutics (NASDAQ:TNGX) Stock Price - MarketBeat
FY2024 Earnings Forecast for TNGX Issued By Leerink Partnrs - Defense World
Leerink Partnrs Brokers Increase Earnings Estimates for TNGX - MarketBeat
EcoR1 Capital sells $8.4 million in Tango Therapeutics stock - Investing.com India
EcoR1 Capital sells $8.4 million in Tango Therapeutics stock By Investing.com - Investing.com Australia
Tango Therapeutics' (TNGX) Buy Rating Reiterated at HC Wainwright - MarketBeat
EcoR1 Capital, LLC Adjusts Stake in Tango Therapeutics Inc - GuruFocus.com
Wedbush Has Pessimistic Outlook of TNGX FY2024 Earnings - Defense World
Wedbush Forecasts Reduced Earnings for Tango Therapeutics - MarketBeat
Tango Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Tango Therapeutics sees $9.67m stock sale by Boxer Capital - Investing.com Nigeria
Tango Therapeutics (NASDAQ:TNGX) Price Target Lowered to $8.00 at Guggenheim - MarketBeat
Tango Therapeutics Advances Cancer Treatment Pipeline - TipRanks
Two to Tango: Brain cancer drugs go further into development - BioWorld Online
Tango stock plunges 28% amid pipeline updates, Q3 earnings report - MSN
Tango stock plunges 28% amid pipeline updates, Q3 earnings report (NASDAQ:TNGX) - Seeking Alpha
U.S. Stock market: Sunnova energy(-42.35%0, Zoomcar(-38.48%), Tango therapeutics(-27.22%) among stock losers during early trading - Business Upturn
Tango Shares Plunge After 3Q Loss, Product Plans - MarketWatch
Tango Therapeutics advances cancer drug into full development By Investing.com - Investing.com Canada
Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program - BioSpace
Tango Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Tango Therapeutics advances cancer drug into full development - Investing.com
Maeve Waldron-Lynch to Join Tango Therapeutics, Inc. as Senior Vice President, Head of Clinical Development - Marketscreener.com
(TNGX) On The My Stocks Page - Stock Traders Daily
Tango Therapeutics (NASDAQ:TNGX) Hits New 52-Week LowTime to Sell? - MarketBeat
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio - Simply Wall St
Tango Therapeutics (NASDAQ:TNGX) Stock Rating Reaffirmed by HC Wainwright - Defense World
Tango Therapeutics (NASDAQ:TNGX) Sets New 12-Month Low After Insider Selling - Defense World
Tango Therapeutics (NASDAQ:TNGX) Reaches New 12-Month Low Following Insider Selling - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Tango Therapeutics target held at $13 by H.C. Wainwright - Investing.com
Tango Therapeutics Inc Stock (TNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):